Navigation Links
Surveyed European Oncologists Assign Greater Patient Share to Johnson & Johnson's Abiraterone Compared With Other Emerging Therapies in Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
Date:9/30/2010

BURLINGTON, Mass., Sept. 30 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, according to surveyed European oncologists, Johnson & Johnson's abiraterone will capture greater patient share than Dendreon's Provenge, AstraZeneca's zibotentan or Bristol-Myers Squibb's ipilimumab in asymptomatic or minimally symptomatic, metastatic castrate-resistant prostate cancer (MCRPC).

According to the new European Physician & Payer Forum report entitled Will Emerging Agents for Prostate Cancer Achieve Acceptance from Payers and Prescribers in Europe?, surveyed oncologists in France, Germany, Italy, Spain and the United Kingdom say that efficacy is overwhelmingly the most important factor dictating the uptake of emerging therapies for MCRPC.

"Emerging agents need to improve efficacy over current standards of care in order to penetrate the market," said Decision Resources Analyst Andrew Merron, Ph.D. "The barrier is lower in the asymptomatic MCRPC setting where clinicians are dependent on hormonal therapies, while barriers are greater in the symptomatic MCRPC setting where Sanofi-Aventis's Taxotere (docetaxel), the gold-standard, is widely prescribed. As a result, most agents in clinical trials are being used in combination with Taxotere for symptomatic MCRPC."

In symptomatic MCRPC, the majority of patients will receive a Taxotere-containing regimen one year following the launch of emerging therapies. Celgene's Revlimid and Bristol-Myers Squibb's Sprycel and zibotentan will compete to partner with Taxotere. After considering reimbursement hurdles in their countries, overall, French and Italian oncologists assign the greatest patient share to Sprycel and zibotentan. However, the greatest patient share of any regimen will be attributed to Taxotere/prednisone alone with no emerging therapy additions.

In non-metastatic castrate-resis
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Surveyed Oncologists Say That the Most Promising Targeted Therapy in Adjuvant Clinical Trials is Avastin for the Treatment of Early-Stage Colorectal Cancer
2. Surveyed Neurologists Anticipate That Less Than 30 Percent of Their Use of Emerging Oral Agents in Multiple Sclerosis Will be in the First Line
3. Carbapenems and Other Agents that Provide Broad-Spectrum Activity are Preferred by Surveyed Physicians for the Treatment of Intra-Abdominal Infections
4. Ninety Eight Percent of Surveyed Rheumatologists Will Prescribe Roches Actemra for Rheumatoid Arthritis
5. Surveyed European Oncologists Cite Cost Most Frequently as the Factor Preventing Their Use of Avastin for Non-Small-Cell Lung Cancer
6. Majority of Surveyed Pharmacy Directors Expect To Cover Pfizers Tanezumab If It Is Approved for the Treatment of Chronic Pain
7. An Acute Migraine Therapy That is Not Contraindicated in Patients With a History of Vascular Disease Would Earn a 45 Percent Patient Share in the United States, According to Surveyed Neurologists
8. In First- and Second-Line Treatment of Clostridium Difficile Infection, Nearly 70 Percent of Surveyed Infectious Disease Specialists and Internists Will Use Fidaxomicin and Nearly Half Will Use CDA1/CDB1
9. For Treatment of Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia, 41 Percent of Surveyed European Hematologist-Oncologists Say MabTheras Favorable Efficacy Profile is the Most Significant Driver of Their Use of This Agent
10. For Multiple Myeloma Treatment, More Surveyed European Clinicians Consider the Combination of Immunomodulatory Agents and Proteasome Inhibitors Promising With Respect to Efficacy Than Any Other Drug Regimen Combinations
11. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... WASHINGTON , April 20, 2015  In ... nation,s healthcare markets, the FTC announced that Cardinal ... it illegally monopolized 25 local markets for the ... hospitals and clinics to pay inflated prices for ... to pay $26.8 million of ill-gotten gains and ...
(Date:4/20/2015)... April 20, 2015  Purdue Pharma, a leading ... Butcher has joined the company as Senior ... will have responsibility for all of Purdue,s efforts ... products that would benefit from our patient-focused commercial ... leader," said Purdue President & CEO Mark ...
(Date:4/20/2015)... YORK , April 20, 2015 ... pump market will continue to be robust; the ... incidence of diabetes, expanding global markets, new product ... there are relatively steady market inhibitors, such as ... an increasing competitive environment. The healthcare market research ...
Breaking Medicine Technology:Cardinal Health Agrees to Pay $26.8 Million to Settle Charges It Monopolized 25 Markets for the Sale of Radiopharmaceuticals to Hospitals and Clinics, says FTC 2Cardinal Health Agrees to Pay $26.8 Million to Settle Charges It Monopolized 25 Markets for the Sale of Radiopharmaceuticals to Hospitals and Clinics, says FTC 3Cardinal Health Agrees to Pay $26.8 Million to Settle Charges It Monopolized 25 Markets for the Sale of Radiopharmaceuticals to Hospitals and Clinics, says FTC 4Cardinal Health Agrees to Pay $26.8 Million to Settle Charges It Monopolized 25 Markets for the Sale of Radiopharmaceuticals to Hospitals and Clinics, says FTC 5Purdue Pharma Names J. Alan Butcher Senior Vice President of Licensing & Business Development 2Kalorama: Insulin Pump Market Growing Robustly 2Kalorama: Insulin Pump Market Growing Robustly 3
... TARRYTOWN, N.Y., Oct. 15 Regeneron Pharmaceuticals, Inc. (Nasdaq: ... the 17th Annual NewsMakers in the Biotech Industry Conference ... for 9:00 a.m. Eastern Time.  The session may be ... on the Investor Relations page.  An archived version of ...
... Oct. 15 EntreMed, Inc. (Nasdaq: ... for the treatment of cancer, today announced that ... Stock Market indicating that it has regained compliance ... Listed Securities ("MVLS") requirement for continued listing on ...
Cached Medicine Technology:EntreMed Receives Notice of NASDAQ Compliance 2
(Date:4/20/2015)... 1% for the Planet , one ... that Kate Williams, the network’s Director of Partnerships, will step ... Williams has been part of 1% for the Planet since ... of the Northern Forest Canoe Trail, a 1% for the ... the stewardship of and advocacy for the outdoors, a commitment ...
(Date:4/20/2015)... 20, 2015 Today the members ... Research Fund-Ovarian Cancer National Alliance-National Ovarian Cancer Coalition ... Team will focus on “DNA Repair Therapies for ... identified DNA repair as a common weakness in ... and early detection of ovarian cancer by developing ...
(Date:4/20/2015)... Grateful Dead originally formed in 1965 ... 1995. The group was more than just about rock music. ... space rock, country, and other genres to put together their ... The group was inducted into the Rock and Roll Hall ... than 35 million records worldwide. This year marks the ...
(Date:4/20/2015)... New York (PRWEB) April 20, 2015 ... Centers for Medicare & Medicaid Services introduced their new ... HCAHPS (Hospital Consumer Assessment of Healthcare Providers and Systems) ... survey asks patients about their experiences during a recent ... results from July 1, 2013 through June 30, 2014 ...
(Date:4/20/2015)... (PRWEB) April 20, 2015 Insuranceautoquote.info has ... find affordable car insurance quotes online . , ... for the best results. Clients should always compare online ... be done on a single website: . http://insuranceautoquote.info ... The questionnaire can be completed in a few minutes ...
Breaking Medicine News(10 mins):Health News:1% for the Planet Announces New CEO 2Health News:1% for the Planet Announces New CEO 3Health News:New Ovarian Cancer Dream Team to Research DNA Repair Therapies 2Health News:New Ovarian Cancer Dream Team to Research DNA Repair Therapies 3Health News:New Ovarian Cancer Dream Team to Research DNA Repair Therapies 4Health News:Grateful Dead Tickets at Levi’s Stadium in Santa Clara: Ticket Down Slashes Grateful Dead Tickets in Santa Clara @ Levi’s Stadium for "Fare Thee Well" 50th Anniversary 2Health News:Northern Westchester Hospital Named a 5-Star Hospital In Medicare's Patient Satisfaction Rating 2Health News:Northern Westchester Hospital Named a 5-Star Hospital In Medicare's Patient Satisfaction Rating 3Health News:Affordable Auto Insurance Quotes Can Be Found Online, Fast and Easy 2
... BOSTON, Sept. 15 The 13th Annual ... (HFSA) today featured a discussion titled "Cardiovascular Disease in ... Chen, Director, Stress Echocardiography Program and Program for Cardiac ... Dr. Chen,s presentation highlights the increased risk of heart ...
... , , , ... HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ... use of Nexavar((R)) (sorafenib) tablets across tumor types - as ... will be presented at the joint 15th European CanCer Organisation ...
... CRANBURY, N.J., Sept. 15 Palatin Technologies, Inc. ... on clinical trial results with PL-3994, its product for heart ... Meeting of the Heart Failure Society of America in Boston. ... of PL-3994 in controlled hypertensive volunteers who were taking antihypertensive ...
... , , , ... abstract artist Susan Olmetti , one must only step ... step into the company of unconventional characters housed in an outlying charismatic ... mid-1800s and currently inhabited by more than 75 locally owned, independent businesses ...
... ALEXANDRIA, Va., Sept. 15 For overweight men ... cholesterol, high blood pressure, high blood sugar/glucose, poor diet and ... efforts to lose weight, according to Building Healthier America, a ... overweight and obesity in the U.S. , , ...
... , , , CAPE ... experiencing growth across a range of sectors. However, the drive ... medical imaging devices. , , (Logo: ... Frost & Sullivan ( http://www.medicaldevices.frost.com ), Overview ...
Cached Medicine News:Health News:Presentation at Annual Meeting Highlights Increased Risk of Heart Failure in Childhood Cancer Survivors 2Health News:Presentation at Annual Meeting Highlights Increased Risk of Heart Failure in Childhood Cancer Survivors 3Health News:Bayer and Onyx Announce Nexavar Data Presentations at the Joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress 2Health News:Bayer and Onyx Announce Nexavar Data Presentations at the Joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress 3Health News:Bayer and Onyx Announce Nexavar Data Presentations at the Joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress 4Health News:Bayer and Onyx Announce Nexavar Data Presentations at the Joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress 5Health News:Bayer and Onyx Announce Nexavar Data Presentations at the Joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress 6Health News:Palatin Technologies, Inc. Announces PL-3994 Poster Presentation at 2009 Heart Failure Society of America Annual Meeting 2Health News:Palatin Technologies, Inc. Announces PL-3994 Poster Presentation at 2009 Heart Failure Society of America Annual Meeting 3Health News:Wine Reception Mixing up one Part Abstract Artist Susan Olmetti, one Part Chicago House Fundraiser, and one Part SIR Spa 2Health News:Building Healthier America Announces the 'High Five' Program Addressing Factors Affecting the Energy Levels of Overweight Men 2Health News:Building Healthier America Announces the 'High Five' Program Addressing Factors Affecting the Energy Levels of Overweight Men 3Health News:Medical Imaging Equipment Finds Significant Uptake in Ghana, Finds Frost & Sullivan 2Health News:Medical Imaging Equipment Finds Significant Uptake in Ghana, Finds Frost & Sullivan 3
Sealing Mat for 96-well, 2.0ml, Deep Well, Square Available Sterile...
96-well Silicone Compression Mat, Bulk...
Silicone Compression Mat, Bulk...
96-well Silicone Expansion Mat, Bulk...
Medicine Products: